Real-world Usage of Bevacizumab-bvzr Biosimilar in US Oncology Practice
February 9th 2022Real-world adoption of bevacizumab-bvzr biosimilar was retrospectively assessed, revealing switching between biosimilars and the reference product and utilization in extrapolated indications and combination regimens.